SESSION TITLE: Lung Cancer II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: In patients of non -small cell lung cancer (NSCLC) with mutations of the epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitor (EGFR-TKI) is treatment of choice. The aim of this study was to analyze clinical features of EGFR mutation exon 19 and 21, including treatment with EGFR-TKIs.